Fig. 3

The anti-GBM effects of RG3039 on patient-derived GBM organoids (GBOs)

(a–b) Growth of GBOs treated with RG3039 (10 µM) or DMSO for 15 days (a) Representative bright-field images of GBOs. Scale bar, 250 μm. (b) Quantification of the ratio of the 2D area at each time point to that at day 0 for the same GBOs (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance, **, p < 0.01, ***, p < 0.001, ****, p < 0.0001

(c) Representative images of H&E staining and IHC staining for Ki67 of GBOs treated with RG3039 (8 µM, 16 µM, or 32 µM) or DMSO for 48 h. Scale bar, 250 μm

(d) Quantification of Ki67⁻positive cell density in GBOs treated with RG3039 (8 µM, 16 µM, or 32 µM) or DMSO in IHC staining (mean ± SEM, n = 3). Statistical analysis by unpaired t-test, NS, no significance

(e) Comparison of IC50 of RG3039 and TMZ in GBOs (n = 14). Statistical analysis by paired t-test, NS, no significance